Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Cardax Pharmaceuticals, BASF Form Agreement - Nutraceuticals World

What are you searching for?

Sign in
Market Updates

Cardax Pharmaceuticals, BASF Form Agreement

Author Image

By: Sean Moloughney

Editor, Nutraceuticals World

Cardax Pharmaceuticals, Inc., Honolulu, HI, has entered into a joint development and supply agreement with BASF Ludwigshafen, Germany. The agreement calls for BASF to exclusively manufacture a specialized form of astaxanthin, a key intermediate used to make Cardax’s proprietary pharmaceutical compound Xancor for cardiovascular inflammatory disease. BASF will produce this material according to cGMP standards and in sufficient quantity for pre-clinical, clinical and eventual commercial use. Also part of the agreement, Cardax has granted BASF an option to a royalty-bearing license for nutraceutical use of the specialized form of astaxanthin. All pharmaceutical applications of Xancor remain the property of Cardax.

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Add Nutraceuticals World as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters